Description:

Size: 100ul

Catalog no.: bs-9458R-A555

Price: 380 EUR

Product details

Modification Site

None

Gene ID Number

51086

Target Antigen

TNNI3K

Tested applications

IF(IHC-P)

French translation

anticorps

Clonality

Polyclonal

Modification

Unmodified

Concentration

1ug per 1ul

Excitation emission

553nm/568nm

Conjugated with

ALEXA FLUOR® 555

Crossreactivity

Human, Mouse, Rat

Clone

Polyclonal antibody

Recommended dilutions

IF(IHC-P)(1:50-200)

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR 555

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-TNNI3K PAb ALEXA FLUOR 555

Specificity

This is a highly specific antibody against TNNI3K.

Long name

TNNI3K Polyclonal Antibody, ALEXA FLUOR 555 Conjugated

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human TNNI3K

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Synonyms

Cardiac ankyrin repeat kinase; CARK; MGC142099; MGC33828; Serine/threonine protein kinase TNN13K; Serine/threonine-protein kinase TNNI3K; TNI3K_HUMAN; TNNI3 interacting kinase; TNNI3-interacting kinase; Tnni3k.

Properties

For facs or microscopy Alexa 1 conjugate.Very high photo stable ALEXA conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

TNNI3K, also known as CARK, is a 936 amino acid serine/threonine-protein kinase that is highly expressed in heart. Overexpression of TNNI3K leads to improved cardiac function by enhancing beating frequency and increasing contractile force and epinephrine response. TNNI3K suppresses phosphorylation of cardiac troponin I and p38/JNK-mediated apoptosis, therefore protecting the myocardium from ischemic injury. Administration of TNNI3K to mice with myocardial infarction improves cardiac performance and attentuates ventricular remodeling, suggesting that TNNI3K could be a promising target in the treatment of cardiac diseases. There are four isoforms of TNNI3K that are produced as a result of alternative splicing events.